These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 26873218)

  • 1. Variations in plasma and urinary lipids in response to enzyme replacement therapy for Fabry disease patients by nanoflow UPLC-ESI-MS/MS.
    Byeon SK; Kim JY; Lee JS; Moon MH
    Anal Bioanal Chem; 2016 Mar; 408(9):2265-74. PubMed ID: 26873218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipidomic profiling of plasma and urine from patients with Gaucher disease during enzyme replacement therapy by nanoflow liquid chromatography-tandem mass spectrometry.
    Byeon SK; Lee JY; Lee JS; Moon MH
    J Chromatogr A; 2015 Feb; 1381():132-9. PubMed ID: 25597892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome.
    Rombach SM; Aerts JM; Poorthuis BJ; Groener JE; Donker-Koopman W; Hendriks E; Mirzaian M; Kuiper S; Wijburg FA; Hollak CE; Linthorst GE
    PLoS One; 2012; 7(10):e47805. PubMed ID: 23094092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid and simple extraction of lipids from blood plasma and urine for liquid chromatography-tandem mass spectrometry.
    Bang DY; Byeon SK; Moon MH
    J Chromatogr A; 2014 Feb; 1331():19-26. PubMed ID: 24491523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid quantitation of globotriaosylceramide in human plasma and urine: a potential application for monitoring enzyme replacement therapy in Anderson-Fabry disease.
    Boscaro F; Pieraccini G; la Marca G; Bartolucci G; Luceri C; Luceri F; Moneti G
    Rapid Commun Mass Spectrom; 2002; 16(16):1507-14. PubMed ID: 12203240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipidomic differentiation of Graves' ophthalmopathy in plasma and urine from Graves' disease patients.
    Byeon SK; Park SH; Lee JC; Hwang S; Ku CR; Shin DY; Yoon JS; Lee EJ; Moon MH
    Anal Bioanal Chem; 2018 Nov; 410(27):7121-7133. PubMed ID: 30135996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Profiling of human urinary phospholipids by nanoflow liquid chromatography/tandem mass spectrometry.
    Kim H; Ahn E; Moon MH
    Analyst; 2008 Dec; 133(12):1656-63. PubMed ID: 19082067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy.
    van Breemen MJ; Rombach SM; Dekker N; Poorthuis BJ; Linthorst GE; Zwinderman AH; Breunig F; Wanner C; Aerts JM; Hollak CE
    Biochim Biophys Acta; 2011 Jan; 1812(1):70-6. PubMed ID: 20851180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative analysis of urinary phospholipids found in patients with breast cancer by nanoflow liquid chromatography-tandem mass spectrometry: II. Negative ion mode analysis of four phospholipid classes.
    Min HK; Kong G; Moon MH
    Anal Bioanal Chem; 2010 Feb; 396(3):1273-80. PubMed ID: 19937430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. On-line high speed lipid extraction for nanoflow liquid chromatography-tandem mass spectrometry.
    Lee JY; Yang JS; Park SM; Byeon SK; Moon MH
    J Chromatogr A; 2016 Sep; 1464():12-20. PubMed ID: 27530420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document.
    Biegstraaten M; Arngrímsson R; Barbey F; Boks L; Cecchi F; Deegan PB; Feldt-Rasmussen U; Geberhiwot T; Germain DP; Hendriksz C; Hughes DA; Kantola I; Karabul N; Lavery C; Linthorst GE; Mehta A; van de Mheen E; Oliveira JP; Parini R; Ramaswami U; Rudnicki M; Serra A; Sommer C; Sunder-Plassmann G; Svarstad E; Sweeb A; Terryn W; Tylki-Szymanska A; Tøndel C; Vujkovac B; Weidemann F; Wijburg FA; Woolfson P; Hollak CE
    Orphanet J Rare Dis; 2015 Mar; 10():36. PubMed ID: 25885911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Top-down and bottom-up lipidomic analysis of rabbit lipoproteins under different metabolic conditions using flow field-flow fractionation, nanoflow liquid chromatography and mass spectrometry.
    Byeon SK; Kim JY; Lee JY; Chung BC; Seo HS; Moon MH
    J Chromatogr A; 2015 Jul; 1405():140-8. PubMed ID: 26087967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative analysis of phosphatidylcholines and phosphatidylethanolamines in urine of patients with breast cancer by nanoflow liquid chromatography/tandem mass spectrometry.
    Kim H; Min HK; Kong G; Moon MH
    Anal Bioanal Chem; 2009 Mar; 393(6-7):1649-56. PubMed ID: 19194696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Agalsidase alfa in pediatric patients with Fabry disease: a 6.5-year open-label follow-up study.
    Schiffmann R; Pastores GM; Lien YH; Castaneda V; Chang P; Martin R; Wijatyk A
    Orphanet J Rare Dis; 2014 Nov; 9():169. PubMed ID: 25425121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary Mulberry Cells as a Biomarker of the Efficacy of Enzyme Replacement Therapy for Fabry Disease.
    Aoyama Y; Ushio Y; Yokoyama T; Taneda S; Makabe S; Nishida M; Manabe S; Sato M; Kataoka H; Tsuchiya K; Nitta K; Mochizuki T
    Intern Med; 2020; 59(7):971-976. PubMed ID: 32238663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzyme replacement therapy stabilized white matter lesion progression in Fabry disease.
    Fellgiebel A; Gartenschläger M; Wildberger K; Scheurich A; Desnick RJ; Sims K
    Cerebrovasc Dis; 2014; 38(6):448-56. PubMed ID: 25502511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced glucosylceramide in the mouse model of Fabry disease: correction by successful enzyme replacement therapy.
    Quinta R; Rodrigues D; Assunção M; Macedo MF; Azevedo O; Cunha D; Oliveira P; Sá Miranda MC
    Gene; 2014 Feb; 536(1):97-104. PubMed ID: 24334116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. On-line two-dimensional capillary strong anion exchange/reversed phase liquid chromatography-tandem mass spectrometry for comprehensive lipid analysis.
    Bang DY; Moon MH
    J Chromatogr A; 2013 Oct; 1310():82-90. PubMed ID: 24001943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitation of argatroban in plasma using liquid chromatography electrospray tandem mass spectrometry (UPLC-ESI-MS/MS).
    Molinaro RJ
    Methods Mol Biol; 2010; 603():57-63. PubMed ID: 20077059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous profiling of lysophospholipids and phospholipids from human plasma by nanoflow liquid chromatography-tandem mass spectrometry.
    Lee JY; Min HK; Moon MH
    Anal Bioanal Chem; 2011 Jul; 400(9):2953-61. PubMed ID: 21499968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.